Group 1 - The core viewpoint of the news is that Shanghai First Pharmaceutical Co., Ltd. experienced a stock price increase of 5.2%, reaching 14.57 yuan per share, with a total market capitalization of 3.25 billion yuan [1] - The company is primarily engaged in pharmaceutical retail and wholesale, established in 1992 and listed in 1994 [1] - The trading volume for the stock was 130 million yuan, with a turnover rate of 4.07% [1] Group 2 - According to data, GF Fund's Guangfa Innovation Upgrade Mixed Fund (002939) entered the top ten circulating shareholders of First Pharmaceutical, holding 2.7467 million shares, which is 1.23% of the circulating shares [2] - The fund has achieved a year-to-date return of 35.77% and a one-year return of 77.71%, ranking 1923 out of 8174 and 1157 out of 7982 in its category, respectively [2] - Since its inception, the fund has generated a return of 155.89% [2] Group 3 - The fund manager Liu Gesong has a tenure of 12 years and 28 days, with a total fund asset size of 29.462 billion yuan and a best return of 145.13% during his tenure [3] - Co-manager Wu Yuanyi has a tenure of 4 years and 353 days, managing assets of 20.478 billion yuan, with a best return of 107.14% [3]

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Meeting Overview - The shareholders' meeting of Shanghai First Pharmaceutical Co., Ltd. was held on September 4, 2025, at the company's office in Shanghai [1] - The meeting was presided over by the vice chairman, Mr. Yao Jun, due to the absence of the chairman, Mr. Zhang Haibo [1] - The voting method combined on-site and online voting, complying with relevant laws and regulations [1] Voting Results - Two ordinary resolutions were presented and approved by the shareholders present at the meeting [2] - For the first resolution regarding the appointment of the auditing firm, 112,412,276 votes (99.7660%) were in favor, with 244,350 votes (0.2169%) against, and 19,300 votes (0.0171%) abstaining [2] - For the second resolution concerning the reappointment of the internal control auditing firm, 112,411,876 votes (99.7657%) were in favor, with 244,750 votes (0.2172%) against, and 19,300 votes (0.0171%) abstaining [2] Legal Compliance - The meeting's procedures, participant qualifications, proposals, and voting processes were confirmed to comply with the Company Law, Securities Law, and other relevant regulations [4] - The resolutions passed during the meeting were deemed legal and valid [4]

证券日报网讯 9月4日晚间，第一医药发布公告称，公司2025年第二次临时股东会于2025年9月4日召 开，审议通过了《关于续聘内部控制审计会计师事务所的议案》等。 （文章来源：证券日报） ...

证券代码：600833 证券简称：第一医药 公告编号：2025-044 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 9 月 4 日 (二)股东会召开的地点：上海市徐汇区小木桥路 681 号 20 楼第三会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 143 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 112,675,926 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 50.5078 | | 份总数的比例（%） | | 上海第一医药股份有限公司 审议结果：通过 (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 因公司董事长张海波先生另有公务，本次会议由公司副董事长姚军先生主持。 会议采用现场投票及网络投票相结合的方式表决， ...

上海市金茂律师事务所 关于上海第一医药股份有限公司 法律意见书 致：上海第一医药股份有限公司 （以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《上海证券交易所 上市公司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》（以下简称 "《自律监管指引 1 号》"）等有关法律、法规和规范性文件以及《上海第一医 药股份有限公司章程》（以下简称"《公司章程》"）而出具。 为出具本法律意见书，本所审查了公司本次股东会的有关文件和材料。本所 得到公司如下保证，即其已提供了本所认为出具本法律意见书所必需的材料，所 提供的原始材料、副本、复印件等材料、口头证言均符合真实、准确、完整的要 求，有关副本、复印件等材料与原始材料一致。 为出具本法律意见书，本所律师按照律师行业公认的业务标准、道德规范和 勤勉尽责精神，就本次股东会的召集、召开程序，出席会议人员的资格，会议议 案，以及会议的表决程序、表决结果的合法有效性发表意见如下： （正文） （引言） 上海第一医药股份有限公司（以下简称"公司"）2025 年第二次临时股东 会（以下简称"本次股东会"）于 2025 年 9 月 4 日在 ...

上海市金茂律师事务所 关于上海第一医药股份有限公司 2025 年第二次临时股东会的 法律意见书 致：上海第一医药股份有限公司 （引言） 上海第一医药股份有限公司（以下简称"公司"）2025 年第二次临时股东 会（以下简称"本次股东会"）于 2025 年 9 月 4 日在上海市徐汇区小木桥路 681 号 20 楼第三会议室召开。上海市金茂律师事务所经公司聘请委派韩春燕律 师、路遥律师（以下简称"本所律师"）出席会议，就本次股东会的召集、召开 程序，出席会议人员资格，会议议案，以及会议的表决程序、表决结果等发表法 律意见。 本法律意见书根据《中华人民共和国公司法（2023 修订）》（以下简称"《公 司法》"）、《中华人民共和国证券法（2019 修订）》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《上海证券交易所 上市公司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》（以下简称 "《自律监管指引 1 号》"）等有关法律、法规和规范性文件以及《上海第一医 药股份有限公司章程》（以下简称"《公司章程》"）而出具。 二、 本次股东会的召开 为出具本法律意见书，本所 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.07% on September 4, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the pharmaceutical commercial sector included: - HeFu China (603122) with a closing price of 6.66, up 1.99% [1] - JianZhiJia (605266) at 21.56, up 1.84% [1] - YiXinTang (002727) at 14.98, up 1.70% [1] - Saily Medical (603716) was the biggest loser, closing at 29.00, down 2.26% [2] Trading Volume and Value - The trading volume and value for selected stocks were as follows: - YiXinTang (002727) had a trading volume of 144,800 hands and a transaction value of 216 million [1] - Saily Medical (603716) recorded a trading volume of 256,800 hands with a transaction value of 759 million [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 169 million from institutional investors, while retail investors had a net inflow of 210 million [2] - Key stocks with significant capital flow included: - BaiYang Pharmaceutical (301015) with a net inflow of 15.09 million from institutional investors [3] - LaoBaiXing (603883) with a net inflow of 13.41 million from institutional investors [3]

证券代码：600833 证券简称：第一医药 公告编号：临2025-043 上海第一医药股份有限公司 关于收到房屋征收补偿款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、本次交易概述 根据上海市黄浦区人民政府《上海市黄浦区人民政府房屋征收决定》（黄府征【2023】4号），上海第 一医药股份有限公司（以下简称"我司""公司"）位于上海市黄浦区四川中路553-555号、四川中路545 号、四川中路639号三处房屋被纳入征收范围。上述三处房屋由我司经营管理，曾主要用于对外出租经 营使用。本次房屋征收单位为"上海市黄浦区住房保障和房屋管理局"，房屋征收实施单位为"上海市黄 浦第五房屋征收服务事务所有限公司"，房屋评估单位为"上海房地产估价师事务所有限公司"。 公司分别于2025年2月11日、2025年2月27日召开了第十届董事会第三十次（临时）会议及2025年第一次 临时股东大会，审议通过了《关于公司拟签订房屋征收补偿协议的议案》，并与房屋征收单位、房屋征 收实施单位签订《上海市国有土地上房屋征收补偿协议》及《黄浦区1 ...

Core Points - The pharmaceutical commercial sector experienced a decline of 0.96% on September 3, with First Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 26.14, up 2.27% with a trading volume of 106,600 shares and a transaction value of 279 million [1] - Yifeng Pharmacy (6666609) closed at 24.93, up 2.09% with a trading volume of 203,900 shares and a transaction value of 507 million [1] - Zhejiang Nongyuan (000705) closed at 9.28, up 0.65% with a trading volume of 207,300 shares and a transaction value of 195 million [1] - Guoyao Co. (600511) closed at 29.34, down 0.44% with a trading volume of 40,900 shares and a transaction value of 120 million [1] - Shanghai Pharmaceutical (601607) closed at 18.48, down 0.65% with a trading volume of 202,100 shares and a transaction value of 373 million [1] - Jiuzhoutong (600998) closed at 5.01, down 0.99% with a trading volume of 437,600 shares and a transaction value of 220 million [1] - Nanjing Pharmaceutical (600713) closed at 4.90, down 1.01% with a trading volume of 168,700 shares and a transaction value of 82.85 million [1] - Jianghe Pharmaceutical (002788) closed at 8.40, down 1.18% with a trading volume of 40,400 shares and a transaction value of 34.10 million [1] - Liuyou Group (603368) closed at 17.96, down 1.32% with a trading volume of 61,800 shares and a transaction value of 111 million [1] - Zhongyao Holdings (000950) closed at 5.16, down 1.34% with a trading volume of 162,400 shares and a transaction value of 84.32 million [1] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 295 million from main funds, while speculative funds had a net inflow of 132 million and retail investors had a net inflow of 164 million [3]